Drug Profile
Research programme: anticancer immunotherapeutics - BrightPath Biotherapeutics
Alternative Names: GRN-1301; Neoantigen therapeutics - BrightPath Biotherapeutics; Neoantigen-based cancer vaccine-BrightPath BiotherapeuticsLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator BrightPath Biotherapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Non-small-cell-lung-cancer in Japan (Parenteral)
- 27 Oct 2017 National Cancer Center Tokyo and BrightPath Biotherapeutics agree to co-develop neoantigen vaccine for Cancer
- 11 Jul 2017 BrightPath Biotherapeutics plans a phase I trial for Non-small cell lung cancer in Japan in 2018 (BrightPath Biotherapeutics website, July 2017)